MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy

被引:131
作者
Boren, Todd [1 ]
Xiong, Yin [1 ]
Hakam, Ardeshir [2 ]
Wenham, Robert [1 ,4 ]
Apte, Sachin [1 ]
Chan, Gina [1 ]
Kamath, Siddharth G. [1 ]
Chen, Dung-Tsa
Dressman, Holly [3 ]
Lancaster, Johnathan M. [1 ,4 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, Div Anat Pathol, Tampa, FL 33612 USA
[3] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA
关键词
Ovarian cancer; MicroRNA; Microarray; Salvage chemotherapy; PHASE-II; EXPRESSION PROFILES; LIPOSOMAL DOXORUBICIN; TOPOTECAN; PLATINUM; CARCINOMA; GEMCITABINE; MODULATE; CELLS; OVEREXPRESSION;
D O I
10.1016/j.ygyno.2009.01.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Few successful therapeutic options exist for patients with recurrent ovarian cancer (OVCA). This is due in part to an incomplete understanding of the molecular determinants of chemotherapy-response. Recently, it has been shown that microRNAs (miRNAs) influence messenger-RNA (mRNA) post-transcriptional control and can contribute to human carcinogenesis. The objective of the current study was to explore the role of miRNAs, and their predicted mRNA targets, in OVCA in-vitro response to chemotherapy. Methods. The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. Results. Twenty-seven miRNAs were found to be associated with response to the one or more of the 6 salvage chemotherapies tested (p < 0.05). Predicted targets of these miRNAs included 52 mRNAs, previously reported to be associated with chemo-responsiveness, and which are also involved in functional biologic pathways that influence cancer cell cytotoxicity, carcinogenesis, cell mitosis, p53 signaling, and tumor cell growth and invasion. Conclusion. We have identified miRNAs and their predicted target mRNAs associated with ovarian cancer cell response to chemotherapeutic agents. Our strategy of integrating miRNA and mRNA data may aid in the characterization of important molecular pathways associated with OVCA chemo-response. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 50 条
[1]  
[Anonymous], 2007, CANC FACTS FIG 2007
[2]  
[Anonymous], MIRBASE MICRORNA SEQ
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[5]   MicroRNAs modulate the chemosensitivity of tumor cells [J].
Blower, Paul E. ;
Chung, Ji-Hyun ;
Verducci, Joseph S. ;
Lin, Shili ;
Park, Jong-Kook ;
Dai, Zunyan ;
Liu, Chang-Gong ;
Schmittgen, Thomas D. ;
Reinhold, William C. ;
Croce, Carlo M. ;
Weinstein, John N. ;
Sadee, Wolfgang .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) :1-9
[6]   MicroRNA expression profiles for the NCI-60 cancer cell panel [J].
Blower, Paul E. ;
Verducci, Joseph S. ;
Lin, Shili ;
Zhou, Jin ;
Chung, Ji-Hyun ;
Dai, Zunyan ;
Liu, Chang-Gong ;
Reinhold, William ;
Lorenzi, Philip L. ;
Kaldjian, Eric P. ;
Croce, Carlo M. ;
Weinstein, John N. ;
Sadee, Wolfgang .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (05) :1483-1491
[7]   Topotecan for the treatment of advanced epithelial ovarian cancer:: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].
Bookman, MA ;
Malmström, H ;
Bolis, G ;
Gordon, A ;
Lissoni, A ;
Krebs, JB ;
Fields, SZ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3345-3352
[8]   MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis [J].
Boren, Todd ;
Xiong, Yin ;
Hakam, Ardeshir ;
Wenham, Robert ;
Apte, Sachin ;
Wei, ZhengZheng ;
Kamath, Siddharth ;
Chen, Dung-Tsa ;
Dressman, Holly ;
Lancaster, Johnathan M. .
GYNECOLOGIC ONCOLOGY, 2008, 110 (02) :206-215
[9]   Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression [J].
Chang, Mee Young ;
Boulden, Janette ;
Sutanto-Ward, Erika ;
Duhadaway, James B. ;
Soler, Alejandro Peralta ;
Muller, Alexander J. ;
Prendergast, George C. .
CANCER RESEARCH, 2007, 67 (01) :100-107
[10]  
Chao Angel, 2007, Taiwan J Obstet Gynecol, V46, P363, DOI 10.1016/S1028-4559(08)60005-4